BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

31 articles for F Kayser

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.EBI
Amgen
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.EBI
Amgen
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.EBI
Amgen
Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.EBI
Amgen
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.EBI
Amgen
Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.EBI
Amgen
Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.EBI
Amgen
Structure guided design of a series of sphingosine kinase (SphK) inhibitors.EBI
Amgen
Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.EBI
Amgen
Rational design and binding mode duality of MDM2-p53 inhibitors.EBI
Amgen
Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.EBI
Amgen
Structure-based design of novel inhibitors of the MDM2-p53 interaction.EBI
Amgen
Discovery and optimization of a series of liver X receptor antagonists.EBI
Amgen
Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction.EBI
Amgen
Discovery of a new binding mode for a series of liver X receptor agonists.EBI
Amgen
Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.EBI
Amgen
Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.EBI
Amgen
Discovery of pyrrolopyridazines as novel DGAT1 inhibitors.EBI
Amgen
The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.EBI
Amgen
Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.EBI
Amgen
Potent Kv1.3 inhibitors from correolide-modification of the C18 position.EBI
Merck Research Laboratories
Benzamide derivatives as blockers of Kv1.3 ion channel.EBI
Merck Research Laboratories
PIPERIDINYLBENZONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEINBDB
Boehringer Ingelheim International
JAK inhibitors containing a 4-membered heterocyclic amideBDB
Theravance Biopharma R&D Ip
Tricyclic compounds as Cyp1 inhibitorsBDB
The General Hospital
Benzamide derivatives as PPAR-gamma modulatorsBDB
Medibiofarma
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitorsBDB
Merck Sharp & Dohme
Bicyclic heteroaryl substituted compoundsBDB
Bristol-Myers Squibb
The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.BDB
Harvard Neurodiscovery Center
Discovery of a Highly Selective STK16 Kinase Inhibitor.BDB
Chinese Academy of Sciences
Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases.BDB
University of Wisconsin